恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

休市中 04-17 16:08:14

66.400

-2.150

-3.14%

最高68.750	最低66.000	成交量325.82万
今开68.750	昨收68.550	日振幅4.01%
总市值4,407亿	流通市值171.31亿	总股本66.37亿
成交额2.17亿	换手率1.26%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":66.4,"timestamp":1776413294003,"preClose":68.55,"halted":0,"volume":3258172,"delay":0,"changeRate":-0.03136396790663737,"floatShares":258000000,"shares":6637000000,"eps":1.3576391828543657,"marketStatus":"休市中","change":-2.15,"latestTime":"04-17 16:08:14","open":68.75,"high":68.75,"low":66,"amount":216994834,"amplitude":0.040117,"askPrice":66.4,"askSize":1200,"bidPrice":66.2,"bidSize":3200,"shortable":3,"etf":0,"ttmEps":1.3576391828543657,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":7,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":68.55,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"volumeRatio":1.0770166402517323,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":56.33,"timestamp":1776409200000,"preClose":57.47,"halted":0,"volume":63252300,"delay":0,"premium":"+2.45"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"1198794886","title":"恒瑞医药将于2026年05月27日派发末期股息每股0.23港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198794886","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198794886?lang=zh_cn&edition=full","pubTime":"2026-04-17 21:51","pubTimestamp":1776433898,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276)\n根据公司最新公告，董事会批准就截至2025年12月31日止年度派发末期股息，每10股派发2.2828港元，折合每股约0.23港元（四舍五入后）。股东批准日期为2026年4月16日，除净日定于2026年4月29日，股东如欲符合收取股息的资格，须于2026年4月30日16:30前递交过户登记文件。公司将于2026年5月4日至2026年5月11日暂停办理股份过户登记，5月11日为记录日期，并预计于2026年5月27日派发股息。\n公告同时更新了派息金额、公司预设派发货币、汇率及代扣所得税信息等。不同类型股东适用的代扣税率最高可达20%，具体以公司公告及相关税务法规为准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628542204","title":"恒瑞医药(01276)将于5月27日派发末期股息每10股2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628542204","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628542204?lang=zh_cn&edition=full","pubTime":"2026-04-17 21:36","pubTimestamp":1776432977,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，由于2025年利润分派方案已于股东会获股东批准，董事会欣然宣布，向全体股东派发现金股息每10股人民币2元(含税)(2025年末期股息)。 2025年末期股息将派付予于2026年5月11日(星期一)(记录日期)名列本公司H股股东名册的H股股东。2025年末期股息预期于2026年5月27日(星期三)向H股股东派发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828714.EUR","LU2580892862.HKD","LU1580142542.USD","LU2148510915.USD","LU2495084118.USD","BK0012","LU2097828805.USD","LU0359202008.SGD","LU1023057109.AUD","LU2097828474.EUR","LU1064131003.USD","LU0359201885.HKD","LU1328615791.USD","BK0183","LU2488822045.USD","LU1146622755.USD","LU1997245177.USD","LU2543165471.USD","LU2097828557.USD","BK4585","LU0405327494.USD","LU1997245094.SGD","LU0359201612.USD","BK0196","BK0028","600276","LU1969619763.USD","01276","LU2580892789.USD","LU1655091616.SGD","LU1255011170.USD","LU2328871848.SGD","BK0060","LU1064130708.USD","BK4588","BK0188","LU2097828631.EUR","BK1191","LU1781817850.SGD","LU1820825898.SGD","LU2289578879.USD","LU1997244956.HKD","BK0239","VIG","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158890283","title":"恒瑞医药(01276)将于2026年05月27日派发末期股息每股0.20元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158890283","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158890283?lang=zh_cn&edition=full","pubTime":"2026-04-17 21:35","pubTimestamp":1776432943,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276)公告称，2025年利润分配方案已在2026年4月16日股东周年大会获得股东批准。公司将向于2026年5月11日（星期一）名列H股股东名册的股东派发2025年末期股息，每10股人民币2元（含税），折合每股人民币0.20元，并将于2026年5月27日（星期三）派付。H股股息以港元结算，每10股约2.28港元（含税），具体换算以大会前五个营业日人民币对港元平均基准汇率为准。公司回购账户所持股份不参与本次派息，若股份总数于记录日期前后发生变动，总派发金额将相应调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628767522","title":"智通AH统计|4月17日","url":"https://stock-news.laohu8.com/highlight/detail?id=2628767522","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628767522?lang=zh_cn&edition=full","pubTime":"2026-04-17 16:15","pubTimestamp":1776413706,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止4月17日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为583.54%、322.20%、299.64%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-22.98%、-19.40%、-6.35%。其中东北电气、安德利果汁、龙源电力的偏离值位居前三，分别为71.60%、40.91%、22.56%；另外，剑桥科技、金风科技、绿色动力环保的偏离值位居后三，分别为-34.23%、-24.88%、-23.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1720050803.USD","01989","01349","02359","EWH","00638","00300","HYDD.SI","LU1688375341.USD","02208","03606","02218","LU0469268626.HKD","01812","01618","00895","03986","01211","06869","LU1961090484.USD","03143","01108","01276","01330","LU0540923850.HKD","02338","02465","01057","06031","02068","00553","02768","01816","81211","03678","01033","002594","03908","BYDDY","03750","03968","159982","399300","00916","SG9999002828.SGD","BK1509","06166","00042","00187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166405575","title":"恒瑞医药将于2026年06月16日派发中期股息每股0.20元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166405575","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166405575?lang=zh_cn&edition=full","pubTime":"2026-04-16 22:56","pubTimestamp":1776351383,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276)2026年4月16日召开2025年股东周年大会，审议并通过了2025年利润分配方案。根据公告安排，公司将向全体股东每10股派发现金分红人民币2元（含税），相当于每股派发0.20元（含税），预计于股东大会结束后2个月内发放，派发日期暂定2026年6月16日。公司同时表示，如在公告发布之日至实施权益分派股权登记日期间总股本发生变动，仍将维持每股分配比例不变，相应调整分配总额。具体登记日和派息安排将另行公告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627121679","title":"恒瑞医药(01276)：注射用SHR-A2102被纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2627121679","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627121679?lang=zh_cn&edition=full","pubTime":"2026-04-16 21:53","pubTimestamp":1776347586,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司子公司上海恒瑞医药有限公司的注射用SHR-A2102被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，这也是SHR-A2102第2次纳入突破性治疗品种。注射用SHR-A2102 已开展多项Ⅰ-Ⅲ期临床研究，涵盖晚期尿路上皮癌、膀胱癌、食管癌、肺癌、头颈癌等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","LU1580142542.USD","600276","LU2097828631.EUR","LU1997245177.USD","BK0060","LU1146622755.USD","LU1255011170.USD","LU2097828557.USD","01276","LU2328871848.SGD","BK0183","BK0239","LU1781817850.SGD","LU1064130708.USD","BK0196","LU0359201612.USD","LU1023057109.AUD","LU2097828714.EUR","BK1191","BK0012","LU1064131003.USD","LU2580892862.HKD","LU1997245094.SGD","LU0359202008.SGD","LU2097828805.USD","LU2488822045.USD","LU1969619763.USD","LU2289578879.USD","LU0405327148.USD","LU2543165471.USD","BK0188","LU1820825898.SGD","LU2148510915.USD","LU2097828474.EUR","LU0405327494.USD","LU2495084118.USD","LU1655091616.SGD","LU1997244956.HKD","LU0359201885.HKD","LU1328615791.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627213970","title":"恒瑞医药(01276)选举孙飘扬为董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2627213970","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627213970?lang=zh_cn&edition=full","pubTime":"2026-04-16 20:47","pubTimestamp":1776343654,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)公布，于 2026 年 4 月 16 日，董事会选举孙飘扬先生为公司第十届董事会董事长，选举戴洪斌先生为公司第十届董事会副董事长。经董事长提名，现聘任冯佶女士为公司总裁并由公司任命为首席运营官，聘任刘笑含女士为公司董事会秘书。经总裁提名，聘任张连山先生、江宁军先生为公司执行副总裁，聘任孙杰平先生、朱国新先生为公司高级副总裁，聘任刘健俊先生为公司首席财务官(财务负责人)。经提名，聘任田飞先生为公司证券事务代表。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2543165471.USD","BK0196","BK0239","LU1781817850.SGD","LU2097828805.USD","LU1328615791.USD","BK0012","LU2488822045.USD","LU2580892862.HKD","LU2097828557.USD","LU1023057109.AUD","LU0359202008.SGD","LU2495084118.USD","LU2580892789.USD","LU2097828631.EUR","LU1997245094.SGD","BK0060","LU1064131003.USD","LU1655091616.SGD","LU2097828714.EUR","LU1146622755.USD","LU0359201612.USD","LU2289578879.USD","01276","BK0028","BK0188","LU2148510915.USD","LU0405327494.USD","LU1969619763.USD","BK0183","LU0359201885.HKD","LU1820825898.SGD","LU1064130708.USD","LU1255011170.USD","LU1580142542.USD","LU2097828474.EUR","LU1997244956.HKD","LU2328871848.SGD","LU0405327148.USD","LU1997245177.USD","600276","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627261720","title":"中金：国家优化创新药新药上市首发价格机制 药品行业有望迎高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2627261720","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627261720?lang=zh_cn&edition=full","pubTime":"2026-04-16 14:24","pubTimestamp":1776320685,"startTime":"0","endTime":"0","summary":"中金主要观点如下：优化创新药等新上市药品首发价格机制，实行新上市药品企业自评制度政策鼓励对于新上市药品价格制定，区分高水平创新药、改良新药、通用名药等情形。根据真实世界研究结果和临床使用实效，医药企业可在药品首发价格基础上适当调整价格水平。促进创新药多元支付与价格合理形成，拓宽创新药支付渠道。风险因素研发不及预期，创新药核心产品对外合作进展不及预期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023057109.AUD","LU2097828805.USD","LU0348827113.USD","LU0417516738.SGD","LU1770034418.SGD","LU2476274308.USD","09606","LU1961090484.USD","159992","09926","HK0000252160.HKD","HK0000500386.USD","LU1719994722.HKD","06160","LU0455707207.USD","LU0348766576.USD","LU2476274720.SGD","BK1588","LU0348784397.USD","LU2399975544.HKD","LU0634319403.HKD","LU0540923850.HKD","LU0348825331.USD","LU0348783233.USD","06990","LU0359202008.SGD","LU0417516902.SGD","IE00B543WZ88.USD","LU1794554557.SGD","06978","LU2097828714.EUR","LU2328871848.SGD","BK1161","LU0196878994.USD","LU0502904849.HKD","LU0307460666.USD","BK1191","LU0561508036.HKD","LU0417516571.SGD","IE00B5MMRT66.SGD","IPOS","LU2097828631.EUR","LU0588546209.SGD","LU2543165471.USD","LU2778985437.USD","HK0000165453.HKD","01276","LU2097828557.USD","01801","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132254462","title":"财报前瞻｜恒瑞医药本季度营收预计稳中向好，机构观点偏谨慎乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1132254462","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132254462?lang=zh_cn&edition=full","pubTime":"2026-04-16 08:37","pubTimestamp":1776299832,"startTime":"0","endTime":"0","summary":"恒瑞医药将于2026年04月23日发布最新季度财报，市场聚焦创新药放量与费用率变化对盈利的影响。目前公开渠道未形成一致可量化预期，也未在上个季度财报中披露本季度的明确指引，因而关于本季度的营收、毛利率、净利润或净利率、调整后每股收益的具体预测数据暂无权威口径可引用。基于近半年内可获得的机构观点检索，市场对恒瑞医药的态度以谨慎乐观为主。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜恒瑞医药本季度营收预计稳中向好，机构观点偏谨慎乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2627856502","title":"恒瑞医药(01276)：HRS-7156片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2627856502","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627856502?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:42","pubTimestamp":1776249773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称“公司”)子公司山东盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于 HRS-7156 片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-7156 片是公司自主研发的1类新药。临床前数据显示，HRS-7156可显着改善心脏功能和病变。经查询，目前国内外暂无同类药物获批上市。截至目前， HRS-7156 片相关项目累计研发投入约为3,760万元(未经审计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","LU1146622755.USD","LU1997245177.USD","LU0359202008.SGD","LU1064130708.USD","LU2289578879.USD","LU2495084118.USD","LU0405327148.USD","LU1328615791.USD","BK0012","BK0196","BK0239","01276","LU2148510915.USD","LU1580142542.USD","LU1781817850.SGD","BK0060","LU2097828474.EUR","LU1969619763.USD","LU1997245094.SGD","LU2097828557.USD","LU1820825898.SGD","BK0028","LU1255011170.USD","LU2097828631.EUR","LU0359201612.USD","LU0359201885.HKD","BK0188","LU2580892862.HKD","LU1997244956.HKD","LU2328871848.SGD","LU2580892789.USD","LU2488822045.USD","BK1191","LU2097828805.USD","LU1023057109.AUD","LU2543165471.USD","600276","LU2097828714.EUR","LU1655091616.SGD","LU1064131003.USD","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627404698","title":"智通AH统计|4月15日","url":"https://stock-news.laohu8.com/highlight/detail?id=2627404698","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627404698?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:15","pubTimestamp":1776240905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止4月15日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为566.67%、319.93%、296.48%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-21.24%、-18.50%、-5.93%。其中东北电气、安德利果汁、北京北辰实业股份的偏离值位居前三，分别为67.60%、32.62%、23.50%；另外，广和通、金风科技、绿色动力环保的偏离值位居后三，分别为-27.07%、-24.37%、-22.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01349","03968","BK1149","LU0287142896.SGD","LU0228659784.USD","03986","03145","LU0762542818.HKD","01618","02865","HPAD.SI","00042","02359","00588","159982","00638","LU0561508036.HKD","BK1506","03908","LU0898667661.SGD","EWH","06869","03678","01330","02338","03750","PNGAY","399300","02208","03143","03969","LU0149534421.HKD","IE00BZ08YR35.GBP","02218","02318","00300","06613","01276","01057","82318","00553","01989","00187","01108","PAImain","00916","601318","02899","09980"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129567719","title":"恒瑞医药：4月14日回购44,000股，耗资约245.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129567719","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129567719?lang=zh_cn&edition=full","pubTime":"2026-04-14 17:10","pubTimestamp":1776157853,"startTime":"0","endTime":"0","summary":"恒瑞医药（股票代码：01276）于2026年4月14日发布公告，称于上海证券交易所回购44,000股A股，用于A股员工持股计划。此次回购占该公司现有已发行股份的约0.0007%，最低每股价格为人民币55.69元，最高每股价格为人民币55.73元，合计付出约人民币2,451,260元（折合约245.13万元）。\n根据公告，此次回购完成后，公司已发行股份数量由6,372,149,824股减少至6,372,105,824股，库藏股数相应增加至6,896,450股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。\n本公告由联席公司秘书刘笑含签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627701419","title":"恒瑞医药(01276)4月14日斥资245.13万元回购4.4万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627701419","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627701419?lang=zh_cn&edition=full","pubTime":"2026-04-14 17:09","pubTimestamp":1776157754,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年4月14日斥资人民币245.13万元回购4.4万股A股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828714.EUR","LU1997244956.HKD","LU2495084118.USD","LU2543165471.USD","159982","BK0028","LU1580142542.USD","LU1820825898.SGD","BK0183","LU0405327148.USD","BK0239","LU2148510915.USD","LU1064130708.USD","LU1023057109.AUD","LU1064131003.USD","LU2097828474.EUR","LU2580892862.HKD","LU2097828557.USD","600276","LU2328871848.SGD","BK0012","LU1997245094.SGD","LU1255011170.USD","LU2097828805.USD","LU0359202008.SGD","BK0060","LU0359201612.USD","LU1781817850.SGD","LU1969619763.USD","LU1146622755.USD","LU1997245177.USD","LU2289578879.USD","LU1328615791.USD","BK1191","LU2580892789.USD","399300","LU1655091616.SGD","BK0188","LU2488822045.USD","LU0405327494.USD","BK0196","LU2097828631.EUR","LU0359201885.HKD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627439545","title":"口服减肥药大战打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2627439545","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627439545?lang=zh_cn&edition=full","pubTime":"2026-04-13 17:24","pubTimestamp":1776072286,"startTime":"0","endTime":"0","summary":"张力制表2026年，减肥药赛道早已告别诺和诺德一家独大的旧格局。随着司美格鲁肽核心化合物专利到期，国内市场迎来全新竞争态势：信达生物玛仕度肽注射液III期临床试验成功达成主要终点，来凯医药、先为达生物等本土企业则加速冲刺港股IPO，试图在资本与市场的双重赛道抢占先机。进入4月份，口服剂型的商业化落地，成为全球减肥药赛道的新焦点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604133702961635.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702961635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600276","IE00BZ1G4Q59.USD","NVOH","BK4007","BK4588","BK4599","LLY","LU0154236417.USD","LU1093756325.SGD","IE00BKVL7J92.USD","IPOS","BK4585","NVO","600745","NVOX","LU1093756168.USD","BK4532","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627343879","title":"智通AH统计|4月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2627343879","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627343879?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:15","pubTimestamp":1776068106,"startTime":"0","endTime":"0","summary":"AH统计|4月13日","market":"us","thumbnail":"https://img.zhitongcaijing.com/images/contents/image_15.png","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/images/contents/image_15.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00347","03969","03986","01330","IE00BVYPNP33.GBP","00187","01349","02701","02208","03143","02865","03347","02338","00042","IE00BF5LJ272.USD","159982","06031","03750","LU0648948544.HKD","02359","01108","00300","LU0072913022.USD","LU1242518857.USD","01989","03968","LU1719994722.HKD","LU0572944931.SGD","06198","LU1064131342.USD","00553","EWH","03606","01276","00638","01033","06869","02899","01057","02715","06613","02218","399300","03678","LU0868486357.SGD","06865","LU1366334578.USD","LU0181495838.USD","00588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626128031","title":"AH溢价走低的成因与展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2626128031","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626128031?lang=zh_cn&edition=full","pubTime":"2026-04-11 17:09","pubTimestamp":1775898556,"startTime":"0","endTime":"0","summary":"文｜财华社恒生沪深港通AH股溢价指数持续走低，从2024年2月接近158点的高位回落，至2026年初为123.48点，现报118.94点，见下图，显示AH股估值差距正逐步收敛。这类高溢价的形成，核心与行业属性及A股资金偏好密切相关。但需注意，当前赴港上市的A股公司以优质龙头为主，其H股定价更受国际资金认可，短期供给冲击有限，难以改变溢价率收敛的整体趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775802053606341910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0320764599.SGD","LU2543165471.USD","LU2148510915.USD","BK0132","LU1048596156.SGD","LU1251922891.USD","LU2242644610.SGD","LU1244550221.USD","LU2506952410.USD","BK1521","BK1171","LU0918141887.USD","LU0871576103.HKD","LU0039217434.USD","LU1115378108.SGD","LU1515016050.SGD","LU1719994722.HKD","BK0278","LU1813983027.USD","300750","LU0326950275.SGD","LU0228367735.SGD","LU0456842615.SGD","02359","LU1152091168.USD","LU0405327148.USD","LU2506952253.HKD","LU2449936058.SGD","01349","LU0449515922.USD","LU1102505762.USD","LU1105468828.SGD","BK1522","LU0417516902.SGD","LU0192582467.USD","LU0384037296.USD","LU2348773727.SGD","LU0348814723.USD","BK0070","688505","LU0359201885.HKD","LU2506951792.HKD","LU0828237510.HKD","LU0543330566.HKD","LU0589944569.HKD","LU1960683339.HKD","LU0244354667.USD","BK0187","LU0979878070.USD","LU0823414478.USD","SG9999002828.SGD","LU1721428347.USD","IE00B3M56506.USD","IE0008368742.USD","LU1861219969.SGD","LU0572944931.SGD","LU1781817850.SGD","BK1163","LU0449509016.USD","LU1244550577.SGD","LU1046422090.SGD","LU0124384867.USD","LU2097828631.EUR","BK1141","LU1226287529.USD","BK1507","03750","LU0326948709.USD","LU0047713382.USD","LU2506952337.HKD","BK4585","LU1328277881.USD","LU2275660780.HKD","LU0261950470.USD","LU0651947912.USD","LU0254981946.USD","BK0010","SG9999001846.SGD","LU0648948544.HKD","LU0269904917.USD","LU0531971595.HKD","LU1224709979.USD","LU0143863198.USD","LU0231483743.USD","LU1808992512.USD","SG9999002463.SGD","LU0672654166.SGD","HK0000181112.HKD","LU0051755006.USD","LU1366334651.USD","LU1993786604.SGD","LU2298064838.USD","LU1969619763.USD","LU1979443071.USD","IE0003851619.USD","IE00BPRC5H50.USD","LU2097828557.USD","LU0708995583.HKD","HK0000181138.USD","BK1562","LU0588546209.SGD","LU2778985437.USD","LU0128522157.USD","00553","LU1244550494.USD","LU2399975544.HKD","LU0611395673.USD","LU0287142896.SGD","LU1303224171.USD","LU0516422440.USD","LU0251143458.SGD","LU0315179316.USD","LU2039709279.SGD","LU2152927971.USD","LU0650527681.SGD","LU1769817179.HKD","LU0043850808.USD","LU0708995153.HKD","LU0918141705.HKD","LU1769817096.USD","IE00BGHQDM52.EUR","LU1934453819.USD","BK1237","IE00BVYPNP33.GBP","LU1997244956.HKD","IE00BD6J9T35.USD","LU1064131003.USD","LU0107464264.USD","LU0052750758.USD","LU1770034418.SGD","LU1868837565.USD","LU1997245177.USD","BK1576","LU2294711713.HKD","LU0163747925.USD","LU0302445910.USD","LU0210526637.USD","03986","IE00BF5LJ272.USD","SG9999014674.SGD","IE00B5MMRT66.SGD","LU2125910500.SGD","SG9999000459.SGD","LU0106259558.USD","603259","LU1039395188.USD","LU0370786039.SGD","LU0868486357.SGD","LU0029875118.USD","LU2360107325.USD","01057","000338","LU2153592121.USD","SG9999003461.SGD","LU0828237940.HKD","LU0561508036.HKD","LU0307460666.USD","LU1939255532.USD","LU0488056044.USD","IE0032431581.USD","LU1580142542.USD","LU2477742899.HKD","LU2580892789.USD","LU0117841782.USD","LU0516423091.SGD","LU0821914370.USD","LU0505663152.USD","LU0456846285.SGD","LU0828238088.HKD","LU0651946864.USD","SG9999001903.USD","03143","LU0067412154.USD","LU0320764755.SGD","LU1366334578.USD","LU0594300179.USD","LU2298322129.HKD","BK1231","02338","LU0348805143.USD","LU0165289439.USD","LU0516422366.SGD","603986","LU0143863784.USD","BK1560","LU1655091616.SGD","LU0594300419.USD","LU1282649141.HKD","LU0011963245.USD","LU0502904849.HKD","LU0593848301.USD","HK0000352291.HKD","LU1868838027.USD","LU0455707207.USD","LU1880383440.USD","HK0000352382.USD","LU0359201612.USD","LU1675838814.USD","03968","LU0431992006.USD","LU0797268264.HKD","LU0229945570.USD","LU0737861699.HKD","BK1583","SGXZ49509284.SGD","LU2580892862.HKD","LU2226246903.HKD","LU0501845795.SGD","LU0054450605.USD","LU2424517915.HKD","LU1188198961.HKD","LU0048575426.USD","BK0028","SG9999006597.SGD","IE0031814852.USD","LU0048580855.USD","LU0605514214.HKD","LU2289578879.USD","LU0181495838.USD","LU0228659784.USD","600775","LU2097828474.EUR","LU0314109678.HKD","BK1116","02218","LU1102505929.USD","LU1152091754.HKD","LU1720050803.USD","LU0072462343.USD","06809","BK0183","LU1880383366.USD","LU0164872284.USD","LU0320764243.SGD","LU0724618433.USD","LU0469268626.HKD","LU1023057109.AUD","LU2495084118.USD","LU1961090484.USD","LU0516422952.EUR","BK0214","BK0102","LU0149534421.HKD","IE00B543WZ88.USD","LU1282648689.USD","IE00B8HQ1Z84.USD","LU0862451753.SGD","LU1146622755.USD","LU0456827905.SGD","LU0509642566.USD","SG9999001689.USD","001236","SGXZ81163826.USD","BK0015","LU0516423174.USD","LU0072913022.USD","LU1978683503.SGD","LU1861214812.USD","BK1610","EVS.SI","LU0880133367.SGD","LU1211504680.USD","LU2294711473.HKD","LU0823426308.USD","LU0634319403.HKD","LU0348735423.USD","LU1831875114.USD","LU2153591404.USD","LU0543330483.HKD","BK0224","LU2249611893.SGD","LU1051768304.USD","LU0048388663.USD","IE00BYV24P56.USD","SG9999004220.SGD","LU0417516738.SGD","IE00B031J352.USD","LU1242518857.USD","IE00BZ08YS42.EUR","LU2328871848.SGD","LU2213484517.USD","IE00B29SXG58.USD","IE00B8L5B284.USD","LU1064130708.USD","LU1051769294.HKD","BK1191","SG9999000327.SGD","LU2045819591.USD","LU0348816934.USD","600276","IE00BVYPNQ40.USD","LU0128522744.USD","BK1144","LU0823437842.USD","LU0531970944.HKD","LU0607220059.USD","LU2357125470.USD","LU0640798160.USD","LU0214875030.USD","IE00BZ08YT58.USD","LU2348774022.SGD","01276","CIHKY","LU2476274720.SGD","600871","03678","BK0188","LU0823426480.USD","LU0328353924.USD","BK1202","LU0540923850.HKD","LU0405327494.USD","IE0008369823.USD","LU1008478684.HKD","LU0259732245.USD","IE00B031HY20.USD","LU0359202008.SGD","LU1048588211.SGD","LU0106959298.USD","LU0173614495.USD","LU1242518931.SGD","688008","LU0312595415.SGD","LU2097828714.EUR","LU0348788117.USD","605198","LU1794554557.SGD","LU0823414551.USD","IE00BMCWC346.EUR","LU1820825898.SGD","LU0791590937.USD","LU2097828805.USD","LU0140636845.USD","LU3063872942.SGD","LU0348827113.USD","LU1255011170.USD","LU0049853897.USD","LU0106252389.USD","LU0348825331.USD","LU1688375341.USD","LU2476274308.USD","LU0791591158.USD","LU0164865239.USD","LU0327786744.USD","LU2238339852.HKD","01033","LU1807302812.USD","BK0012","BK0125","BK1149","LU0188438112.USD","LU0890818403.SGD","LU1282649810.SGD","LU0463099449.HKD","BK1564","BK4588","IE00BZ08YR35.GBP","LU1997245094.SGD","LU0029874905.USD","BK1147","002703","IE0034224299.USD","IE0003795394.USD","LU0132412106.USD","LU1282649067.USD","IE00BZ199S13.USD","600036"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626193994","title":"恒瑞医药(01276)：HRS-5765片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626193994","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626193994?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:07","pubTimestamp":1775812071,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称“公司”)子公司成都盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于 HRS-5765 片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-5765 片是公司自主研发的 1 类新药，临床前数据显示，HRS-5765 可显著改善心脏功能和病变。经查询，目前国内外暂无同类药物获批上市。截至目前， HRS-5765 片相关项目累计研发投入约 1,380 万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828714.EUR","LU1997244956.HKD","LU2495084118.USD","LU2543165471.USD","BK0028","LU1580142542.USD","LU1820825898.SGD","BK0183","LU0405327148.USD","BK0239","LU2148510915.USD","LU1064130708.USD","LU1023057109.AUD","LU1064131003.USD","LU2097828474.EUR","LU2580892862.HKD","LU2097828557.USD","600276","LU2328871848.SGD","BK0012","LU1997245094.SGD","LU1255011170.USD","LU2097828805.USD","LU0359202008.SGD","BK0060","LU0359201612.USD","LU1781817850.SGD","LU1969619763.USD","LU1146622755.USD","LU1997245177.USD","LU2289578879.USD","LU1328615791.USD","BK1191","LU2580892789.USD","LU1655091616.SGD","BK0188","LU2488822045.USD","LU0405327494.USD","BK0196","LU2097828631.EUR","LU0359201885.HKD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183475270","title":"摩根士丹利增持恒瑞医药H股 持股比例从1.17%跃升至9.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183475270","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183475270?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:33","pubTimestamp":1775727201,"startTime":"0","endTime":"0","summary":"根据香港交易所最新披露的数据显示，国际投行摩根士丹利对江苏恒瑞医药H股的持仓出现显著变动。截至4月1日，其持有的多头头寸比例由原先的1.17%大幅提升至9.85%，增幅超过8个百分点。\n这一持股变动反映出摩根士丹利对恒瑞医药未来发展的强烈信心。作为国内创新药龙头企业，恒瑞医药近年来持续加大研发投入，其产品管线覆盖抗肿瘤、麻醉、造影剂等多个重点领域。\n此次持股比例的大幅提升，可能与国际资本看好中国医药行业长期发展潜力相关。在带量采购政策常态化背景下，具备核心创新能力的药企有望获得更多市场关注。机构投资者持仓变动往往被视为行业风向标，此次增持行为或引发市场对创新药板块的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","LU0405327148.USD","01276","LU0405327494.USD","LU2328871848.SGD","BK0196","LU2543165471.USD","LU2580892789.USD","LU0359202008.SGD","LU0359201885.HKD","LU1328615791.USD","600276","LU1820825898.SGD","LU2097828714.EUR","LU2289578879.USD","LU1023057109.AUD","LU1255011170.USD","LU2495084118.USD","LU2148510915.USD","LU1969619763.USD","LU1064131003.USD","LU1997245094.SGD","LU2097828557.USD","BK0060","BK0012","BK1191","LU1580142542.USD","LU1997245177.USD","LU1064130708.USD","LU2097828805.USD","LU2580892862.HKD","LU0359201612.USD","BK0183","LU2097828631.EUR","LU1781817850.SGD","LU1146622755.USD","BK0239","LU2488822045.USD","LU2097828474.EUR","BK0188","LU1997244956.HKD","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902875","title":"智通AH统计|4月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626902875?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:15","pubTimestamp":1775722506,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止4月9日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为583.54%、311.23%、293.19%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-26.20%、-14.52%、-6.13%。其中东北电气、安德利果汁、新华文轩的偏离值位居前三，分别为81.94%、23.71%、21.28%；另外，浙江世宝、京城机电股份、凯盛新能的偏离值位居后三，分别为-33.20%、-29.23%、-29.13%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01108","01330","03969","06031","02866","LU0868486357.SGD","00568","HK0000306685.HKD","IE00B5MMRT66.SGD","03606","EWH","03986","03369","01276","LU0828238088.HKD","159982","02359","03968","00042","LU0708995583.HKD","03143","00638","02899","02218","LU2097828474.EUR","00553","IE00BZ08YR35.GBP","02865","01349","LU1831875114.USD","02338","00300","06865","03200","LU1808992512.USD","LU1366334651.USD","02208","02691","03268","IE0032431581.USD","01057","03750","01033","03678","06869","LU0455707207.USD","399300","00187","00811"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625796100","title":"恒瑞医药(01276)4月7日斥资362.15万元回购6.48万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625796100","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625796100?lang=zh_cn&edition=full","pubTime":"2026-04-08 06:30","pubTimestamp":1775601039,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年4月7日斥资362.15万元回购6.48万股A股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU1997245177.USD","LU1820825898.SGD","LU2289578879.USD","LU2495084118.USD","BK0239","BK0060","BK0183","LU1997244956.HKD","399300","159982","LU1328615791.USD","LU1997245094.SGD","600276","LU1023057109.AUD","LU0359201612.USD","BK1191","01276","LU1655091616.SGD","LU1781817850.SGD","LU1969619763.USD","LU2580892862.HKD","LU0405327148.USD","LU2097828631.EUR","BK0012","LU0405327494.USD","LU0359202008.SGD","LU1255011170.USD","BK0028","LU2097828557.USD","LU2488822045.USD","LU2328871848.SGD","BK0196","LU2097828714.EUR","LU1064131003.USD","LU1146622755.USD","LU2097828474.EUR","LU1064130708.USD","LU2097828805.USD","LU1580142542.USD","LU0359201885.HKD","LU2580892789.USD","BK0188","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":0.0137},{"period":"3month","weight":-0.141},{"period":"6month","weight":-0.1547},{"period":"1year","weight":0.5074},{"period":"ytd","weight":-0.0681}],"compareEarnings":[{"period":"1week","weight":0.0103},{"period":"1month","weight":0.0052},{"period":"3month","weight":-0.0255},{"period":"6month","weight":0.0362},{"period":"1year","weight":0.2227},{"period":"ytd","weight":0.0207}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}